Cell proliferation in renal cell carcinoma — a comparative study of cell kinetic methods

[1]  G. Roos,et al.  Proliferating cell nuclear antigen expression in renal cell carcinoma. Prognostic implications. , 1996, Scandinavian journal of urology and nephrology.

[2]  G. Roos,et al.  Proliferation of human renal cell carcinoma studied with in vivo iododeoxyuridine labelling and immunohistochemistry. , 1994, Scandinavian journal of urology and nephrology.

[3]  G. Wilson,et al.  Cell kinetics of renal cell carcinoma studied with in vivo iododeoxyuridine incorporation and flow cytometry. , 1994, The Journal of urology.

[4]  G. Roos,et al.  Tumor‐cell proliferation and prognosis in renal‐cell carcinoma , 1993, International journal of cancer.

[5]  M. Tachibana,et al.  Bromodeoxyuridine and deoxyribonucleic acid bivariate analysis in human renal cell carcinoma. Does flow cytometric determination predict malignant potential or prognosis of patients with renal cell carcinoma? , 1992, American journal of clinical pathology.

[6]  D. Lane,et al.  Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. , 1991, Journal of clinical pathology.

[7]  N. Shepherd,et al.  The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S + G2 + M phase fraction (flow cytometric analysis) and prognosis , 1991, Histopathology.

[8]  P. Hall,et al.  Review: assessment of cell proliferation in histological material. , 1990, Journal of clinical pathology.

[9]  Rochelle L. Garcia,et al.  Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. , 1989, The American journal of pathology.

[10]  M. I. Saunders,et al.  Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. , 1988, British Journal of Cancer.

[11]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[12]  G. Roos,et al.  DNA content in renal cell carcinoma with reference to tumor heterogeneity , 1985, Cancer.

[13]  W. Greco,et al.  Proliferative characteristics of primary and metastatic human solid tumors by DNA flow cytometry. , 1984, Cytometry.

[14]  B. Franza,et al.  Identity of the proliferating cell nuclear antigen and cyclin , 1984, Nature.

[15]  M. Köllermann,et al.  Flow cytometric and autoradiographic studies of human kidney carcinomas surgically removed after preirradiation. , 1980, The British journal of cancer. Supplement.

[16]  G. Heninger,et al.  PHENOXYBENZAMINE IN ANOREXIA NERVOSA , 1976, The Lancet.

[17]  W. Göhde,et al.  The applications of the BrdUrd-technique for the estimation of cycling S-phase cells in human renal cell carcinoma , 2004, Urological Research.

[18]  B. Zackrisson,et al.  Cell kinetics of head and neck squamous cell carcinomas. Prognostic implications. , 1994, Acta oncologica.

[19]  K. Teague,et al.  Comparative flow cytometric analysis of proliferating cell nuclear antigen (PCNA) antibodies in human solid neoplasms. , 1994, Cytometry.

[20]  B. Tribukait,et al.  Comparative study of proportion of S-phase cells in ascites and pleural effusions in ovarian carcinoma using antibromodeoxyuridine monoclonal antibody and DNA flow-cytometry. , 1989, Acta oncologica.

[21]  R. Colvin,et al.  Diagnosis and management of renal cell carcinoma A clinical and pathologic study of 309 cases , 1971, Cancer.